A research paper by A-Cube has been published in the prestigious international journal in dermatology, THE JOURNAL OF DERMATOLOGY.
Dr. Kazuki Matsuda, Assistant Professor and Chief of the Department of Dermatology at the University of Tokyo Hospital, together with his colleagues, investigated the relationship between anti-SS-A antibodies (anti-SSA) and the prognosis of systemic sclerosis. They conducted an analysis focusing on cases with isolated anti-SS-A antibody positivity, using the novel autoantibody measurement technology “Research Test A-Cube®.” Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular damage, fibrosis, and immune abnormalities, which can severely affect life prognosis when the disease progresses. Previous reports have suggested that anti-SS-A antibodies, detected in some patients, may be associated with severe clinical manifestations.
In this study, 307 Japanese patients who visited the Department of Dermatology at the University of Tokyo Hospital between 2011 and 2020 were analyzed. The results revealed that patients with isolated anti-SS-A antibody positivity are more likely to experience unfavorable disease progression and poor life prognosis. The findings highlight the importance of regular evaluation of anti-SSA antibodies and demonstrate that continuous monitoring of autoantibodies can help predict disease risk. This study also showed that disease-specific autoantibodies not identifiable by conventional insurance-covered tests may be detected by A-Cube, thereby uncovering autoantibodies associated with severe clinical outcomes. These results contribute to improving the accuracy of diagnosis and prognosis prediction in systemic sclerosis.
For further details, please refer to the published paper:
Isolated Anti-SS-A Antibody Seropositivity as a Poor Prognostic Factor in Systemic Sclerosis: Insights From a Cohort of 307 Cases
Nana Ishida, Kazuki M. Matsuda, Hirohito Kotani, Hayakazu Sumida, Shinichi Sato